Abstract:Timothy M Rawson, 1– 3 David B Antcliffe, 2, 4 Richard C Wilson, 1– 3 Alireza Abdolrasouli, 5 Luke SP Moore 1, 6, 7 1 Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Hammersmith Hospital, London, UK; 2 Centre for Antimicrobial Optimisation, Imperial College London, Imperial College London, London, UK; 3 David Price Evan's Group in Infectious Diseases and Global Health, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK; 4 Division Anaesthesia, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Imperial College London, London, UK; 5 Department of Medical Microbiology, King's College Hospital, London, UK; 6 Chelsea & Westminster NHS Foundation Trust, London, UK; 7 North West London Pathology, Imperial College Healthcare NHS Trust, London, UK Correspondence: Timothy M Rawson, Health Protection Research Unit in Healthcare Associated Infections & Antimicrobial Resistance, Hammersmith Hospital, Du Cane Road, London, W12 0NN, United Kingdom, Email Bacterial and fungal infections are common issues for patients in the intensive care unit (ICU). Large, multinational point prevalence surveys have identified that up to 50% of ICU patients have a diagnosis of bacterial or fungal infection at any one time. Infection in the ICU is associated with its own challenges. Causative organisms often harbour intrinsic and acquired mechanisms of drug-resistance, making empiric and targeted antimicrobial selection challenging. Infection in the ICU is associated with worse clinical outcomes for patients. We review the epidemiology of bacterial and fungal infection in the ICU. We discuss risk factors for acquisition, approaches to diagnosis and management, and common strategies for the prevention of infection. Keywords: bacterial infection, fungal infection, critical care, diagnostics, therapeutics Bacterial and fungal infections are common diagnoses for patients in the intensive care unit (ICU). 1 In 2017, Vincent et al reported a 24-hour point prevalence survey of 1150 centres in 88 countries. 2 Of 15,165 patients with infection data available, 8135 (54%) had proven or suspected infection and 10,640 (70%) received at least one antimicrobial agent. Secondary infection acquired in the ICU was observed in 1760/8135 (22%). 2 Gram-negative organisms predominated (3540/5259; 67%) in those with clinically significant microbiology and fungal infection accounted for 16% (864/5259) of cases. 2 These data were similar to the previous multinational point prevalence studies, such as EPIC II that was performed in 2009 and reported that 51% of patients were considered infected, antibiotics were prescribed for 71% of patients, and Gram-negative infections accounted for 62% and fungal infections 19% of cases. 3 Mortality rates in the ICU are higher in patients with bacterial or fungal infection compared to those without infection. 2–9 In-hospital mortality for ICU patients with infection is approximately 30%. 2 Secondary bacterial or fungal infection and the presence of drug-resistant infections are independent risk factors for mortality with an increased odds of death compared to community-acquired infection (OR: 1.32; 95% CI 1.10–1.60). 2 Infections in the ICU are frequently caused by drug-resistant bacteria and increasingly drug-tolerant/resistant fungi. 3,7,10 Termed antimicrobial resistance (AMR), these infections already have a significant impact on hospitalised patients. Globally, rates of AMR will vary between regions. 11,12 Gram-negative organisms pose a major challenge including extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriales, derepressed AmpC organisms, carbapenemase-producing Enterobacteriales (CPE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa . 12 Gram-positive challenges include methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide-resistant Enterococcus (GRE) species . 12 Antifungal tolerant and resistant fungal infections are an emerging threat, 13,14 not least given the high rate of associated mortality in critical care, and the relative inability to rapidly diagnose and deliver effective antimicrobial therapy. 13 Among fungal pathogens, the global emergence and spread of multidrug-resistant Candida auris has caused several healthcare-associated outbreaks. 15–17 Blood stream infections among non- albicans Candida species with decreased susceptibility to first-line antifungal -Abstract Truncated-

Strategies to limit invasive fungal infection in a coronavirus disease 2019 (COVID-19) intensive care unit: The role of infection prevention for renovation and construction in resource-limited settings

An outbreak within an outbreak: The impact of Infection Prevention and Control strategies on hospital-acquired infections and the occurrence of multi-drug resistant organisms during the COVID-19 pandemic

Architectural design strategies for infection prevention and control (IPC) in health-care facilities: towards curbing the spread of Covid-19

Infection Prevention and Control Strategies According to the Type of Multidrug-Resistant Bacteria and Candida auris in Intensive Care Units: A Pragmatic Resume including Pathogens R0 and a Cost-Effectiveness Analysis

Anesthesia Management and Perioperative Infection Control in Patients with the Novel Coronavirus

Infection control challenges in setting up community isolation and treatment facilities for patients with coronavirus disease 2019 (COVID-19): Implementation of directly observed environmental disinfection

Resilient Hospital Design: From Crimean War to COVID-19

Candida auris outbreak at a tertiary care hospital during the COVID-19 pandemic

The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature

Influences of healthcare workers' behaviours towards infection prevention and control practices in the clinical setting: A systematic review

Healthcare facilities in low- and middle-income countries affected by COVID-19: Time to upgrade basic infection control and prevention practices

Fungal infection profile in critically ill COVID-19 patients: a prospective study at a large teaching hospital in a middle-income country

Nosocomial infections among COVID-19 patients: an analysis of intensive care unit surveillance data

Management of Bacterial and Fungal Infections in the ICU: Diagnosis, Treatment, and Prevention Recommendations

Compliance of healthcare workers in a psychiatric inpatient ward to infection control practices during the COVID-19 pandemic: a participant observation study supplemented with a self-reported survey

What US hospitals are doing to prevent common device-associated infections during the coronavirus disease 2019 (COVID-19) pandemic: Results from a national survey in the United States

Infection Prevention during the Coronavirus Disease 2019 Pandemic

Coronavirus disease 2019 (COVID-19) pandemic, central-line–associated bloodstream infection (CLABSI), and catheter-associated urinary tract infection (CAUTI): The urgent need to refocus on hardwiring prevention efforts

How to Defeat Multidrug-Resistant Bacteria in Intensive Care Units. A Lesson from the COVID-19 Pandemic. Prevention, Reservoirs, and Implications for Clinical Practice

ISCCM Position Statement on the Management of Invasive Fungal Infections in the Intensive Care Unit

Infection prevention and control (IPC) implementation in low-resource settings: a qualitative analysis